Viatris (VTRS) Cash from Investing Activities Growth (3y) (2022 - 2026)
Viatris (VTRS) Cash from Investing Activities Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.92 Bn | 42.96 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.19 Bn | 39.53 Bn | 2.15 Bn | -53.63% |
| 3 | Zoetis | 31.74 Bn | 30.06 Bn | 1.05 Bn | -55.36% |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.87 Bn | 5.10 Bn | 34.35% |
| 5 | United Therapeutics | 22.22 Bn | 19.56 Bn | 683.80 Mn | 33.61% |
| 6 | Viatris | 18.71 Bn | 17.83 Bn | 1.46 Bn | 15.92% |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | -2.45% |
| 8 | Elanco Animal Health | 11.80 Bn | 11.27 Bn | 798.00 Mn | -36.76% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.47 Bn | 397.90 Mn | -26.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 15.92% |
| Mar 31, 2026 | 33.33% |
| Dec 31, 2025 | -28.49% |
| Sep 30, 2025 | 4.90% |
| Jun 30, 2025 | 13.85% |
| Mar 31, 2025 | 0.91% |
| Dec 31, 2024 | 8.34% |
| Sep 30, 2024 | 156.05% |
| Jun 30, 2024 | 189.92% |
| Mar 31, 2024 | -38.43% |
| Dec 31, 2023 | 47.32% |
| Mar 31, 2023 | -72.66% |
| Dec 31, 2022 | 74.44% |